Riley Cote, former NHL enforcer, discusses his advocacy for psychedelics and psychedelic-assisted therapy on the Psychedelic Spotlight Podcast.
Similar Posts
Field Trip And Wesana Make Major Moves | FTRP, WESA
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Field Trip Press Release: https://www.globenewswire.com/news-
release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development
Field Trip Health:
In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.
Wesana:
On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.
@psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor
What to expect at a Co-Therapy Retreat Centre With Andrew Tansil
In this episode, we get into what to expect at a Psychedelic Retreat that offers Co-Therapy, and some serious transformational energy. Listen to Andrew from Sayulita Wellness Retreat speak about his life-changing revelation, and the reasons why folks come to Psychedelic Retreats.
My 5-MeO-DMT Psychedelic Experience in Tepotzlan Mexico | Tandava Retreats
In this short vlog, Swati Sharma, Media Director of PsychedelicSpotlight.com…
Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund
This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.
Top 10 Psychedelic Stocks To Own According To PSIL ETF (MNMD, CMPS, ATAI, NUMI & MORE)
Top 10 Psychedelic stocks to own according to PSIL ETF (DO I AGREE?)
What’s up Psychedelic Investors!?! Today we are looking at the actively managed Psychedelic Medicines ETF, PSIL, run by Advisor Shares.
Before we get into that though, make sure you go check out psychedelicspotlight.com and sign up for their weekly newsletter. I am featured in each one, with a 3:30 clip summarizing the biggest events in the psychedelic medicines world over the past week. It is essential!
On today’s episode we go through each of the top ten holding in PSIL, including MindMed (MNMD /MMED), Compass Pathways (CMPS), atai Life Sciences (atai), Cybin (CYBN), Field Trip (FTRP), Numinus, (NUMI) and more.
For some of the lesser known companies, such as Seelos Therapeutics, Wesana Health and GreenBrook TMS, we give a brief rundown of the company.
Investing in an actively managed psychedelic stocks ETF can be a great opportunity for those who believe in the ability of psychedelics to heal mental health issues such as PTSD and depression, but are not sure which companies are best to invest in. PSIL is actively managed, which means that their team of experts are picking what they believe to be the best stocks in the industry.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PSIL #ThePsychedelicInvestor
HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)
HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?
Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.
HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.
Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.
The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .
https://havnlife.com/
CSE: HAVN | OTC: HAVLF | FRA: 5NP
#HAVN #HAVNLifeSciences #Mindmed